top of page
gradientForSurfBreak.png

Item List

Dec 20, 2022
Newswires
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC).

Recent Posts

Portfolio Company

Carlsmed.png

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Pr ...

Carlsmed

Feb 10, 2026

Portfolio Company

Carlsmed.png

xCures and the Colorectal Cancer Alliance Partner to Support Patient Access and ...

The National Law Review

Feb 5, 2026

Portfolio Company

Carlsmed.png

Vanguards of Health Care: Carlsmed Personalizes Spine with AI ...

Bloomberg

Feb 5, 2026

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page